Prevention of herpes simplex virus diseases in man.
D000212:Acyclovir / Q000627:therapeutic use; D000818:Animals; D000914:Antibodies, Viral / Q000276:immunology; D000920:Antibody-Dependent Cell Cytotoxicity; D000956:Antigens, Viral / Q000276:immunology; D002986:Clinical Trials as Topic; D006561:Herpes Simplex / Q000188:drug therapy / Q000276:immunology / Q000517:prevention & control*; D006801:Humans; D007065:Idoxuridine / Q000627:therapeutic use; D007231:Infant, Newborn; D018139:Simplexvirus / Q000276:immunology*; D014271:Trifluridine / Q000627:therapeutic use; D014611:Vaccination; D014740:Vidarabine / Q000627:therapeutic use; D014765:Viral Vaccines
D000914:Antibodies, Viral; D000956:Antigens, Viral; D014765:Viral Vaccines; D014740:Vidarabine; D007065:Idoxuridine; D014271:Trifluridine; D000212:Acyclovir